An Open Label, Phase 1b, Single CENTER, Ascending Dose Study TO ASSESS THE SAFETY AND TOLERABILITY of DM199 With a Comparative Pharmacokinetic Study of DM199 Administered Intravenously and a Bioavailability Assessment of Subcutaneous Administration of DM199 in Normal Healthy Subjects

Trial Profile

An Open Label, Phase 1b, Single CENTER, Ascending Dose Study TO ASSESS THE SAFETY AND TOLERABILITY of DM199 With a Comparative Pharmacokinetic Study of DM199 Administered Intravenously and a Bioavailability Assessment of Subcutaneous Administration of DM199 in Normal Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs DM 199 (Primary) ; DM 199 (Primary)
  • Indications Acute kidney injury; Diabetic nephropathies; Nephritis; Stroke; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors DiaMedica Therapeutics
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2017 Results published in a DiaMedica media release.
    • 26 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top